Meeting
2016 ASCO Annual Meeting
Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity.
Authors
John Ben Liao
University of Washington, Seattle, WA
John Ben Liao , Denise Cecil , Yushe Dang , Kelsey K. Baker , Kelsie J Ovenell , Jessica Reichow , Stephanie Parker , Doreen Higgins , Jennifer Childs , Elizabeth Kyungsun Broussard , Andrew L. Coveler , Lupe G. Salazar , Barbara Ann Goff , Mary Weber Redman , Mary L. Disis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01322802
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5542)
DOI
10.1200/JCO.2016.34.15_suppl.5542
Abstract #
5542
Poster Bd #
365
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.
First Author: William Rayford Gwin III
Poster
2013 ASCO Annual Meeting
Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.
First Author: Neil Lorne Berinstein
Poster
2011 ASCO Annual Meeting
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in adults with solid tumor malignancy (STM).
First Author: K. M. Mullane
Poster
2024 ASCO Annual Meeting
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
First Author: Maha H. A. Hussain